Literature DB >> 26915655

Non-invasive respiratory support for infants in low- and middle-income countries.

Erik A Jensen1, Aasma Chaudhary2, Zulfiqar A Bhutta3, Haresh Kirpalani4.   

Abstract

The overwhelming majority of neonatal deaths worldwide occur in low- and middle-income countries. Most of these deaths are attributable to respiratory illnesses and complications of preterm birth. The available data suggest that non-invasive continuous positive airway pressure (CPAP) is a safe and cost-effective therapy to reduce neonatal morbidity and mortality in these settings. Bubble CPAP compared to mechanical ventilator-generated CPAP reduces the need for subsequent invasive ventilation in newborn infants. There are limited data on the safety and efficacy of high-flow nasal cannulae in low- and middle-income countries, requiring further study prior to widespread implementation.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Continuous positive airway pressure; High-flow nasal cannula; Low- and middle-income; Low-resource; Respiratory distress syndrome

Mesh:

Year:  2016        PMID: 26915655     DOI: 10.1016/j.siny.2016.02.003

Source DB:  PubMed          Journal:  Semin Fetal Neonatal Med        ISSN: 1744-165X            Impact factor:   3.926


  8 in total

Review 1.  CPAP treatment for children with pneumonia in low-resource settings.

Authors:  Eric D McCollum; Andrew G Smith; Michelle Eckerle; Tisungane Mvalo; Katherine L O'Brien; Abdullah H Baqui
Journal:  Lancet Respir Med       Date:  2017-11-10       Impact factor: 30.700

2.  Short term evaluation of respiratory effort by premature infants supported with bubble nasal continuous airway pressure using Seattle-PAP and a standard bubble device.

Authors:  Stephen E Welty; Craig G Rusin; Larissa I Stanberry; George T Mandy; Alfred L Gest; Jeremy M Ford; Carl H Backes; C Peter Richardson; Christopher R Howard; Thomas N Hansen; Charles V Smith
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

3.  The Effect of the Treatment with Heated Humidified High-Flow Nasal Cannula on Neonatal Respiratory Distress Syndrome in China: A Single-Center Experience.

Authors:  Ge Zheng; Xiao-Qiu Huang; Hui-Hui Zhao; Guo-Xing Jin; Bin Wang
Journal:  Can Respir J       Date:  2017-01-12       Impact factor: 2.409

4.  Bubble continuous positive airway pressure for children with high-risk conditions and severe pneumonia in Malawi: an open label, randomised, controlled trial.

Authors:  Eric D McCollum; Tisungane Mvalo; Michelle Eckerle; Andrew G Smith; Davie Kondowe; Don Makonokaya; Dhananjay Vaidya; Veena Billioux; Alfred Chalira; Norman Lufesi; Innocent Mofolo; Mina Hosseinipour
Journal:  Lancet Respir Med       Date:  2019-09-24       Impact factor: 30.700

Review 5.  Barriers and facilitators to implementing bubble CPAP to improve neonatal health in sub-Saharan Africa: a systematic review.

Authors:  Mai-Lei Woo Kinshella; Celia R Walker; Tamanda Hiwa; Marianne Vidler; Alinane Linda Nyondo-Mipando; Queen Dube; David M Goldfarb; Kondwani Kawaza
Journal:  Public Health Rev       Date:  2020-04-28

Review 6.  Respiratory distress syndrome management in resource limited settings-Current evidence and opportunities in 2022.

Authors:  Osayame A Ekhaguere; Ikechukwu R Okonkwo; Maneesh Batra; Anna B Hedstrom
Journal:  Front Pediatr       Date:  2022-07-29       Impact factor: 3.569

7.  Successful Deployment of High Flow Nasal Cannula in a Peruvian Pediatric Intensive Care Unit Using Implementation Science-Lessons Learned.

Authors:  Katie R Nielsen; Rosario Becerra; Gabriela Mallma; José Tantaleán da Fieno
Journal:  Front Pediatr       Date:  2018-04-11       Impact factor: 3.418

8.  Implementing bubble continuous positive airway pressure in a lower middle-income country: a Nigerian experience.

Authors:  Chiamaka Aneji; Tyler Hartman; Oluyinka Olutunde; Ikechukwu Okonkwo; Eghosa Ewumwen; Oniyire Adetiloye; Joseph de Graft-Johnson; Chinyere Ezeaka; Angela Okolo; Ngozi Ibeziako; Obumneme Ezeanosike; Patricia Medupin; George Little
Journal:  Pan Afr Med J       Date:  2020-09-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.